Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Rod who wrote (7059)	3/26/1998 8:53:00 AM
From: Eric Freeman	Read Replies (1) \| Respond to of 8116

Reality at last? Everything can fall into place if we get our costs down. This a key piece in the puzzle. Focus on what we can accomplish, sell or find a a partner for the rest, and stop the dilution of shareholder equity.It is not like Cytogen will not benefit, one way or the other, with ALT - , but it will not bring us down. It sends a strong signal that management is finally moving in the right direction.(Or that they have a plan to begin with) Couple this with increasing sales of existing products, and some smart deals that make us money, and I can see profit by year end. Eric

To: Rod who wrote (7059)	3/26/1998 9:15:00 AM
From: irwin kweller	Read Replies (2) \| Respond to of 8116

Rod, Been a Lurker and shareholder for some time now. I think the report is a good start. I also think from all the volume in the past few days, there's more to it. This news had to be known by the large investors prior to the announcement. Would this news create such large trading volume,or in your opinion is there more to this story? How will Market react today to the news.? Can be taken in both positive and negative mode. Your opinion. Thanks, Irwin

To: Rod who wrote (7059)	3/26/1998 10:30:00 AM
From: BlueCrab	Respond to of 8116

Hiya, Father Rod -- Nice call on the ALT halt. Been monitoring both SI and Yahoo boards and like very much what I see. As I posted over there, this news makes CYTO a buy again for me. This puts all the good product news in the proper context - take PSMA/Prostascint, Quad, ALT and even Oncoscint, wrap them all in a tidier and more efficient package and let 'em show their stuff. A year or so ago I said that CYTO is worth $12; I see no reason to change that estimate. They're actively marketing P'scint, let's hope thay do the same for Quad... Jeff